Skip to main content

Table 1 Participants with both eyes evaluated by treatment arm, pre-treatment mfAC category and timepoint

From: Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

PreTx mfAC

Moxidectin

Ivermectin

Any

0

 

1–5

 

6–10

 

11–20

 

21–40

 

 > 40

 

Any

0

 

1–5

 

6–10

 

11–20

 

21–40

 

 > 40

 

Time

N

n

%

n

%

n

%

n

%

n

%

%

n

N

n

%

n

%

n

%

n

%

n

%

n

%

PreTx

973

596

61.3

183

18.8

59

6.1

67

6.9

52

5.3

16

1.6

490

289

59.0

96

19.6

29

5.9

45

9.2

18

3.7

13

2.7

D4

973

596

61.3

183

18.8

59

6.1

67

6.9

52

5.3

16

1.6

490

289

59.0

96

19.6

29

5.9

45

9.2

18

3.7

13

2.7

M1

967

592

61.2

181

18.7

59

6.1

67

6.9

52

5.4

16

1.7

488

287

58.8

96

19.7

29

5.9

45

9.2

18

3.7

13

2.7

M6

956

586

61.3

179

18.7

58

6.1

65

6.8

52

5.4

16

1.7

487

287

58.9

95

19.5

29

6.0

45

9.2

18

3.7

13

2.7

M12

941

574

61.0

180

19.1

57

6.1

63

6.7

51

5.4

16

1.7

476

281

59.0

93

19.5

28

5.9

43

9.0

18

3.8

13

2.7

M18

758

449

59.2

145

19.1

49

6.5

56

7.4

46

6.1

13

1.7

382

223

58.4

69

18.1

28

7.3

36

9.4

15

3.9

11

2.9

  1. D4: Day 4 post-treatment; M1, M6, M12, M18: Month 1, 6, 12 and 18 post-treatment; mfAC: live microfilariae in the anterior chamber of the eye; PreTx: pre-treatment, percentage calculated for each timepoint by treatment arm
Back to article page

Parasites & Vectors

ISSN: 1756-3305

Contact us